Patents by Inventor David G. Lonergan

David G. Lonergan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IRE-1? inhibitors
    Patent number: 9981901
    Abstract: Compounds which directly inhibit IRE-1? activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response and can be used as single agents or in combination therapies.
    Type: Grant
    Filed: November 18, 2016
    Date of Patent: May 29, 2018
    Assignee: FOSUN ORINOVE PHARMATECH, INC.
    Inventors: John B. Patterson, David G. Lonergan, Gary A. Flynn, Qingping Zeng, Peter V. Pallai
  • IRE-1alpha INHIBITORS
    Publication number: 20170152206
    Abstract: Compounds which directly inhibit IRE-1? activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response and can be used as single agents or in combination therapies.
    Type: Application
    Filed: November 18, 2016
    Publication date: June 1, 2017
    Inventors: John B. Patterson, David G. Lonergan, Gary A. Flynn, Qingping Zeng, Peter V. Pallai
  • IRE-1? inhibitors
    Patent number: 9546149
    Abstract: Compounds which directly inhibit IRE-1? activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response and can be used as single agents or in combination therapies.
    Type: Grant
    Filed: December 15, 2015
    Date of Patent: January 17, 2017
    Assignee: MannKind Corporation
    Inventors: John B. Patterson, David G. Lonergan, Gary A. Flynn, Qingpeng Zeng, Peter V. Pallai
  • IRE-1alpha Inhibitors
    Publication number: 20160168116
    Abstract: Compounds which directly inhibit IRE-1? activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response and can be used as single agents or in combination therapies.
    Type: Application
    Filed: December 15, 2015
    Publication date: June 16, 2016
    Inventors: John B. Patterson, David G. Lonergan, Gary A. Flynn, Qingpeng Zeng, Peter V. Pallai
  • IRE-1alpha INHIBITORS
    Publication number: 20110065162
    Abstract: Compounds which directly inhibit IRE-1? activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response and can be used as single agents or in combination therapies.
    Type: Application
    Filed: November 8, 2010
    Publication date: March 17, 2011
    Applicant: MANNKIND CORPORATION
    Inventors: JOHN B. PATTERSON, DAVID G. LONERGAN, GARY A. FLYNN, QINGPING ZENG, PETER V. PALLAI
  • IRE-1? inhibitors
    Patent number: 7858666
    Abstract: Compounds which directly inhibit IRE-1? activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response and can be used as single agents or in combination therapies.
    Type: Grant
    Filed: June 9, 2008
    Date of Patent: December 28, 2010
    Assignee: MannKind Corporation
    Inventors: John B. Patterson, David G. Lonergan, Gary A. Flynn, Qingping Zeng, Peter V. Pallai
  • IRE-1alpha INHIBITORS
    Publication number: 20090186893
    Abstract: Compounds which directly inhibit IRE-1? activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response and can be used as single agents or in combination therapies.
    Type: Application
    Filed: June 9, 2008
    Publication date: July 23, 2009
    Applicant: MANNKIND CORPORATION
    Inventors: John B. PATTERSON, David G. LONERGAN, Gary A. FLYNN, Qingping ZENG, Peter V. PALLAI